JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation

Secondary malignancies are the most feared adverse effects of cancer therapies. In this study, we explored the cutaneous oncogenic effects of the JAK inhibitor ruxolitinib. First, we demonstrated an epidemiological association between ruxolitinib exposure and development of aggressive cutaneous squamous cell carcinoma (cSCC) by analyzing international pharmacovigilance data and conducting a large cohort study. We next demonstrated the causal link between ruxolitinib treatment and cSCC development using in vitro and in vivo models. Mechanistically, we revealed that ruxolitinib induces transformation of premalignant keratinocytes by activating the MAPK pathway. This effect is mostly driven by JAK2 inhibition, suggesting a pharmacological class effect. To unravel the mechanistic underpinnings of ruxolitinib-induced MAPK activation, we then applied a phosphoproteomic approach. Alternative MAPK signaling downstream of the kinase COT was pinpointed as the main activator of the pathway in this context. The central role of COT was functionally validated using chemical inhibition, genetic impairment, and inactivated COT mutant expression. Indeed, impairment of COT rescued the pro-oncogenic effect of ruxolitinib. Finally, we determined using a combination of epidemiological, in vitro, and in vivo studies that ruxolitinib-mediated oncogenic effects also result in an increased risk of melanoma, suggesting that the uncovered cellular signaling mechanism might be extrapolated to other cancers with a high dependency on the MAPK pathway.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Investigation
Published
2026-11-01
DOI
https://doi.org/10.1172/jci199141
Primary Topic
Nonmelanoma Skin Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation

Damarys Loew, Antoine Forget, Samia Mourah, Lionel Adès et al.
1 links
Journal of Clinical Investigation
Nonmelanoma Skin Cancer Studies
article

JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation

Damarys Loew, Antoine Forget, Samia Mourah, Lionel Adès, Jean‐Jacques Kiladjian, Bérangère Lombard, Juliette Soret‐Dulphy, Célèste Lebbé, Camille Lobry, Hélène Pasquer, Alexandre Puissant, Lina Benajiba, Emmanuelle Latour, Khansa Saadallah, Jérôme Lambert, Pernelle Noïze, Fanélie Jouenne, Emmanuel Raffoux, Amandine Gouverneur, Sophie Tartare‐Deckert, Raphael Marie, Maxime Battistella, Barouyr Baroudjian, Cécile Culeux, Bruno Cassinat, Blandine Roux, Maxime Demourgues, Léa Provent
article en

Abstract

Secondary malignancies are the most feared adverse effects of cancer therapies. In this study, we explored the cutaneous oncogenic effects of the JAK inhibitor ruxolitinib. First, we demonstrated an epidemiological association between ruxolitinib exposure and development of aggressive cutaneous squamous cell carcinoma (cSCC) by analyzing international pharmacovigilance data and conducting a large cohort study. We next demonstrated the causal link between ruxolitinib treatment and cSCC development using in vitro and in vivo models. Mechanistically, we revealed that ruxolitinib induces transformation of premalignant keratinocytes by activating the MAPK pathway. This effect is mostly driven by JAK2 inhibition, suggesting a pharmacological class effect. To unravel the mechanistic underpinnings of ruxolitinib-induced MAPK activation, we then applied a phosphoproteomic approach. Alternative MAPK signaling downstream of the kinase COT was pinpointed as the main activator of the pathway in this context. The central role of COT was functionally validated using chemical inhibition, genetic impairment, and inactivated COT mutant expression. Indeed, impairment of COT rescued the pro-oncogenic effect of ruxolitinib. Finally, we determined using a combination of epidemiological, in vitro, and in vivo studies that ruxolitinib-mediated oncogenic effects also result in an increased risk of melanoma, suggesting that the uncovered cellular signaling mechanism might be extrapolated to other cancers with a high dependency on the MAPK pathway.

Journal of Clinical InvestigationVol. 136(21)
Université de Bordeaux (FR), Inserm (FR), University of California, San Francisco (US), Université Côte d'Azur (FR), Université Paris Cité (FR), Université Paris Sciences et Lettres (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Assistance Publique – Hôpitaux de Paris (FR), Bordeaux Population Health (FR), Centre Méditerranéen de Médecine Moléculaire (FR), Hôpital Saint-Louis (FR), Institut de recherche Saint-Louis (FR), Centre d'Investigation Clinique Saint-Louis (FR), Institut Curie (FR)
Good health and well-being
Openalex Percentile: Top 12%
Nonmelanoma Skin Cancer Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon